Epilepsy patients set to benefit from non-invasive, real-time molecular breath analysis
Deep Breath Intelligence has recently launched ‘DBI-EPIbreath’, a simple breath test that can provide reliable estimates of circulating concentrations of the anti-seizure medication (ASM) valproic acid to aid patient management. This innovative diagnostics tool was be showcased at the European Epilepsy Congress in Geneva, Switzerland, 9-13 July.